PL2520654T3 - Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych - Google Patents

Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych

Info

Publication number
PL2520654T3
PL2520654T3 PL12003146T PL12003146T PL2520654T3 PL 2520654 T3 PL2520654 T3 PL 2520654T3 PL 12003146 T PL12003146 T PL 12003146T PL 12003146 T PL12003146 T PL 12003146T PL 2520654 T3 PL2520654 T3 PL 2520654T3
Authority
PL
Poland
Prior art keywords
inhibitors
compositions
treatment
methods
serine protease
Prior art date
Application number
PL12003146T
Other languages
English (en)
Polish (pl)
Inventor
Leland Shapiro
Original Assignee
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Colorado, A Body Corporate filed Critical The Regents Of The University Of Colorado, A Body Corporate
Publication of PL2520654T3 publication Critical patent/PL2520654T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12003146T 2003-08-26 2004-08-26 Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych PL2520654T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49770303P 2003-08-26 2003-08-26

Publications (1)

Publication Number Publication Date
PL2520654T3 true PL2520654T3 (pl) 2017-08-31

Family

ID=34216145

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12003146T PL2520654T3 (pl) 2003-08-26 2004-08-26 Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych

Country Status (8)

Country Link
US (8) US7850970B2 (OSRAM)
EP (3) EP2520654B8 (OSRAM)
JP (1) JP2007504144A (OSRAM)
CA (1) CA2536918A1 (OSRAM)
DK (1) DK2520654T3 (OSRAM)
ES (1) ES2622522T3 (OSRAM)
PL (1) PL2520654T3 (OSRAM)
WO (1) WO2005019434A2 (OSRAM)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051625A1 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051624A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
EP1704867A1 (en) * 2005-03-18 2006-09-27 Crossbeta Biosciences B.V. Cross-beta structures on microbial organisms
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
US8067187B2 (en) 2005-07-13 2011-11-29 Crossbeta Biosciences B.V. Cross-β structure binding compounds
CA2671322A1 (en) * 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions by administering an actin modulating agent
EP2004678A1 (en) * 2006-03-15 2008-12-24 Csir Modulation of glutamine synthetase activity
US20140147441A1 (en) * 2006-09-12 2014-05-29 The General Hospital Corporation Compositions containing alpha-1-antitrypsin and methods for use
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20110038917A1 (en) * 2007-05-08 2011-02-17 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
HUE038428T2 (hu) * 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
ES2332645B1 (es) 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
WO2011007612A1 (ja) * 2009-07-13 2011-01-20 不二製油株式会社 経口性抗炎症剤及び経口性抗炎症ペプチド
AU2010289417B2 (en) 2009-09-02 2015-08-13 Synedgen, Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP2723370A4 (en) * 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
RU2642310C2 (ru) * 2011-06-28 2018-01-24 ИНХИБРКС ЭлЭлСи Слитые серпиновые полипептиды и способы их применения
IL214246B (en) * 2011-07-21 2018-08-30 Shafferman Avigdor Vaccines produced from htra-defective Bacillus anthraxis
US10220002B2 (en) 2011-12-02 2019-03-05 Board Of Regents Of The University Of Nebraska Controlled-release peptide compositions and uses thereof
DK3381461T3 (da) 2012-01-09 2021-05-17 Serpin Pharma Llc Peptider og fremgangsmåder til anvendelse deraf
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
PL2855506T3 (pl) 2012-05-25 2017-11-30 Well Resources Limited Peptydy i ich zastosowanie
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014197524A2 (en) * 2013-06-06 2014-12-11 Serpin Pharma, Llc Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies
CN103804484B (zh) * 2014-01-24 2016-03-16 南京必优康生物技术有限公司 一种网红细胞生长因子及其制备方法和应用
EP3155117A4 (en) * 2014-06-11 2017-11-22 Beth Israel Deaconess Medical Center, Inc. Alpha1-antitrypsin compositions and methods of treating autoimmune diseases
EP4420518A3 (en) 2014-09-11 2024-11-20 Synedgen, Inc. Compositions and methods of use thereof
IL308589A (en) * 2014-10-27 2024-01-01 Inhibrx Inc Serpin-fused polypeptides and methods of using them
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11723864B2 (en) 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
CA2996975C (en) 2015-08-28 2022-02-15 Serpin Pharma, Llc Methods for treatment of diseases
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US12031144B2 (en) 2017-03-29 2024-07-09 Cornell University Oxidation-resistant AAT gene therapy
WO2019178472A1 (en) * 2018-03-16 2019-09-19 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
US11717519B2 (en) 2017-04-21 2023-08-08 Washington University In St. Louis Use of fatty acid oxidation inhibitors as antimicrobials
AU2020444897A1 (en) * 2020-04-30 2022-12-08 Synedgen, Inc. Compositions and methods of use thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
GB202214206D0 (en) * 2022-09-28 2022-11-09 Chariot Innovations Ltd Treatment
WO2024261179A1 (en) * 2023-06-22 2024-12-26 Aatec Medical Gmbh Recombinant aat from yeast to treat bacterial respiratory infections

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US500242A (en) * 1893-06-27 Superheating steam-coil
DE930013C (de) 1952-02-13 1955-07-07 E Gerspacher Fa Fuellhalter
GB800250A (en) 1956-03-27 1958-08-20 Chimie Atomistique New isonicotinic thioamides and their process of preparation
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US4668504A (en) 1970-11-18 1987-05-26 Merck & Co., Inc. Use of substituted propenoates to prevent nephrotoxicity of certain antibiotics
US3781268A (en) 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
GB1472700A (en) 1974-11-01 1977-05-04 Ono Pharmaceutical Co Guanidinobehzoic acid derivatives and process for preparing the same
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5470241A (en) 1977-11-09 1979-06-05 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
GB2044760B (en) 1979-03-01 1983-03-23 Ono Pharmaceutical Co Guanidinobenzoic acid derivatives
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
JPS5634662A (en) 1979-08-31 1981-04-06 Ono Pharmaceut Co Ltd Guanidinobenzoic acid derivative and its preparation
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
JP2599585B2 (ja) 1984-06-19 1997-04-09 トランスジ−ン ソシエテ アノニム ヒトα▲下１▼−アンチトリプシン誘導体及びその製造法
US4760130A (en) 1984-12-06 1988-07-26 Synergen Biologicals, Inc. Serine protease inhibitors and methods for isolation of same
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4788603A (en) 1985-10-19 1988-11-29 Fuji Photo Film Co., Ltd. Camera for sequentially photographing a subject using a reference optical system and a telescopic optical system
US5247084A (en) 1985-11-12 1993-09-21 Ono Pharmaceutical Co., Ltd. Derivatives of p-guanidinobenzoic acid
US4843094A (en) 1985-11-12 1989-06-27 Ono Pharmaceutical Co., Ltd. Derivatives of p-guantidinobenzoic acid and pharmaceutical agents containing them as active ingredient
ATE67180T1 (de) 1985-11-12 1991-09-15 Ono Pharmaceutical Co P-guanidinbenzoesaeurederivate und pharmazeutische mittel, die sie als aktiven inhaltsstoff enthalten.
US4629567A (en) 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
US5157019A (en) 1986-03-18 1992-10-20 Monsanto Company Serine protease inhibitors
US4713224A (en) 1986-03-31 1987-12-15 The Boc Group, Inc. One-step process for purifying an inert gas
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4829052A (en) 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5114917A (en) * 1986-12-24 1992-05-19 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
KR880012221A (ko) 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4829054A (en) * 1987-04-13 1989-05-09 Miles Laboratories, Inc. Method of decreasing lung damage in a host following the onset of gram negative septicemia/endotoxemia
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4963583A (en) 1987-10-05 1990-10-16 Ciba-Geigy Corporation Beta-ionone derivatives as antifungal agents
US4857538A (en) * 1987-11-30 1989-08-15 The Research Foundation Of State University Of New York New compounds for the study and treatment of microfilament organization in cells
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US4963654A (en) 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5019573A (en) 1989-09-19 1991-05-28 Euroceltique, S.A. Substituted dibenzofurans and methods of using same
JP2568281B2 (ja) 1989-11-17 1996-12-25 原田工業株式会社 自動車用三波共用アンテナ
US5714140A (en) 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
DE4009117A1 (de) 1990-03-19 1991-09-26 Schering Ag Neue leukotrien-b(pfeil abwaerts)4(pfeil abwaerts)-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1991018883A1 (en) 1990-06-07 1991-12-12 Smithkline Beecham Corporation Amide linked pyridyle-benzoic acid derivatives for treating leukotriene-related diseases
JPH07116150B2 (ja) 1990-06-07 1995-12-13 スミスクライン・ビーチャム・コーポレイション 安息香酸誘導体
AU7999691A (en) 1990-06-07 1991-12-31 Smithkline Beecham Corporation Phthalamic acids and their isomers for treating leukotriene-related diseases
WO1991018880A1 (en) 1990-06-07 1991-12-12 Smithkline Beecham Corporation Benzoic acid derivatives for treating leukotriene-related diseases
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5134119A (en) * 1990-10-16 1992-07-28 Lezdey John Treatment of inflammation using 358 substituted alpha-antitrypsin
ES2096665T3 (es) * 1990-10-16 1997-03-16 John Lezdey Tratamiento de la inflamacion.
JP2548587Y2 (ja) * 1990-11-30 1997-09-24 シチズン時計株式会社 プリンタの印字ヘッド
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
JPH06509327A (ja) * 1991-04-18 1994-10-20 ザ　ユー　エー　ビー　リサーチ　ファンデーション エラスターゼ抑制のための組成とその方法
US5175253A (en) * 1991-04-24 1992-12-29 Washington University Binding peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5216022A (en) * 1991-12-19 1993-06-01 Cortech, Inc. Aromatic esters of phenylenedialkanoates as inhibitors of human neutrophil elastase
EP0670737A4 (en) 1992-03-26 1996-05-29 Gensia Inc IN VIVO PEPTIDE THERAPY.
GB9209032D0 (en) 1992-04-25 1992-06-10 Ciba Geigy Ag New peptide derivatives
US5734014A (en) 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
JP2736952B2 (ja) 1992-09-18 1998-04-08 小野薬品工業株式会社 アミジノフェノール誘導体およびその誘導体を有効成分として含有する薬剤
DE4242390A1 (de) 1992-12-09 1994-06-16 Schering Ag Neue Leukotiren-B¶4¶-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5604201A (en) 1993-01-08 1997-02-18 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization Methods and reagents for inhibiting furin endoprotease
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
EP0656349B1 (en) 1993-12-03 1998-04-08 Ono Pharmaceutical Co., Ltd. Amidinophenol derivatives having phospholipase A2 inhibitory activity
JPH0827371A (ja) 1994-05-09 1996-01-30 Japan Carlit Co Ltd:The 紫外線及び赤外線吸収樹脂組成物
US6090786A (en) 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5712117A (en) * 1995-02-08 1998-01-27 Zymogenetics, Inc. Cytoplasmic antiproteinase-2 and coding sequences
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
DK0871454T3 (da) 1995-07-17 2004-03-22 Cephalon Inc Phosphorholdige inhibitorer af cystein- og serinprotease
AU6977096A (en) 1995-09-14 1997-04-01 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
KR100490807B1 (ko) 1995-11-28 2005-10-14 세파론, 인코포레이티드 시스테인및세린프로테아제의d-아미노산함유억제제
EP0900791A1 (en) * 1995-12-27 1999-03-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
KR20000005312A (ko) 1996-04-10 2000-01-25 오노 야꾸힝 고교 가부시키가이샤 트립타아제 억제제 및 신규 구아니디노 유도체
JPH10265452A (ja) 1996-05-24 1998-10-06 Ono Pharmaceut Co Ltd フェニルスルホンアミド誘導体
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
AU3232597A (en) 1996-06-18 1998-01-07 Warner-Lambert Company Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors
WO1997049679A1 (en) 1996-06-27 1997-12-31 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6372887B1 (en) 1996-11-07 2002-04-16 Heska Corporation Flea serine protease inhibitor proteins
JP2002514192A (ja) 1996-11-13 2002-05-14 セフアロン・インコーポレーテツド ベンゾチアゾおよび関連の複素環基を含有するシステインおよびセリンプロテアーゼ阻害剤
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
SI0950067T1 (sl) 1996-11-27 2007-12-31 Genentech Inc Afinitetno čiščenje polipeptida na proteinskemA matriksu
TR200103270T2 (tr) 1996-12-06 2003-03-21 Cortech, Inc. Serin proteas inhibitörleri
US6150332A (en) 1997-01-09 2000-11-21 Virginia Commonwealth University Method and composition for lowering low density lipoprotein cholesterol
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
JP2001524117A (ja) 1997-05-02 2001-11-27 アクゾ・ノベル・エヌ・ベー セリンプロテアーゼ阻害剤
HUP0002951A3 (en) 1997-05-08 2002-10-28 Smithkline Beecham Corp Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5929049A (en) 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
US6197294B1 (en) 1998-10-26 2001-03-06 Neurotech S.A. Cell surface molecule-induced macrophage activation
WO2000044390A1 (en) 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
GB9904421D0 (en) 1999-02-25 1999-04-21 Univ Edinburgh Telecommunications receiver
EP1161532A1 (en) * 1999-03-01 2001-12-12 Human Genome Sciences, Inc. Human serpin proteins
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051623A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
WO2000051625A1 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2000052034A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
AU3923000A (en) 1999-04-16 2000-11-02 Amgen, Inc. Agp-1 fusion protein compositions and methods
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
EP1231936A2 (en) * 1999-10-27 2002-08-21 K-Quay Enterprises, LLC Methods and compositions for treatment of keratoconus using protease inhibitors
JP2003515325A (ja) 1999-12-01 2003-05-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４ジスルフィドコアドメイン含有（ｆｄｃｄ）ポリヌクレオチド、ポリペプチド、および抗体
CN1328000A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——糖基磷脂酰肌醇聚糖f11.22和编码这种多肽的多核苷酸
US6955845B1 (en) 2000-06-30 2005-10-18 Owens Corning Fiberglas Technology, Inc. Acoustical and thermal insulator
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7247704B2 (en) * 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
MXPA03006043A (es) 2001-01-04 2004-01-26 Vascular Biogenics Ltd Metodos que emplean y composiciones que contienen moleculas asociadas en placa para la prevencion y el tratamiento de la aterosclerosis.
PL374045A1 (en) 2001-02-23 2005-09-19 Immunex Corporation Efficient recovery of correctly refolded proteins
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
EP1390497A2 (en) 2001-05-25 2004-02-25 Genset Human cdnas and proteins and uses thereof
US7001884B2 (en) * 2001-06-18 2006-02-21 Regents Of The University Of Michigan Eglin c based drugs for treatment of disease
CA2451026C (en) 2001-06-22 2013-12-10 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US6924267B2 (en) * 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
EP1463942B2 (en) * 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
WO2003068934A2 (en) 2002-02-14 2003-08-21 Rutter William J Chimeric molecules for cleavage in a treated host
AU2003245325A1 (en) * 2002-05-23 2003-12-12 Chiron Corporation Substituted quinazolinone compounds
AU2003252178A1 (en) * 2002-07-25 2004-02-16 Advances Life Sciences, Inc. Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
AU2003296378A1 (en) * 2002-12-06 2004-06-30 Arriva Pharmaceuticals, Inc. Methods and compositions for treatment of otitis media
US20040220242A1 (en) * 2003-05-02 2004-11-04 Leland Shapiro Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions
ES2622522T3 (es) * 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
US20070238655A1 (en) 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
RU2356909C2 (ru) 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
CA2860173C (en) 2004-05-12 2021-12-14 The Brigham And Women's Hospital, Inc. Determining plasma gelsolin level to predict risk of developing infection
CA2671322A1 (en) 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions and methods for treating actin-mediated medical conditions by administering an actin modulating agent
WO2008033890A2 (en) * 2006-09-12 2008-03-20 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008100470A2 (en) 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
JP2010524971A (ja) * 2007-04-20 2010-07-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト 顕著なセリンプロテアーゼ阻害剤活性を有さないアルファ−１アンチトリプシン
US20110077383A1 (en) 2007-07-03 2011-03-31 Medimmune, Llc Hinge domain engineering
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
WO2014160768A1 (en) 2013-03-29 2014-10-02 The Regents Of The University Of Colorado Compositions and methods for preparing a subject for organ or non-organ implantation

Also Published As

Publication number Publication date
EP1660094A2 (en) 2006-05-31
US20140370036A1 (en) 2014-12-18
EP2520654B8 (en) 2017-04-19
JP2007504144A (ja) 2007-03-01
US20140234310A1 (en) 2014-08-21
EP2520654B1 (en) 2017-02-01
US20050106151A1 (en) 2005-05-19
US7850970B2 (en) 2010-12-14
WO2005019434A3 (en) 2005-10-06
CA2536918A1 (en) 2005-03-03
DK2520654T3 (en) 2017-05-01
US9695229B2 (en) 2017-07-04
EP2520654A1 (en) 2012-11-07
ES2622522T3 (es) 2017-07-06
EP3192872A1 (en) 2017-07-19
US20120071545A1 (en) 2012-03-22
WO2005019434A2 (en) 2005-03-03
US10913790B2 (en) 2021-02-09
US20110021416A1 (en) 2011-01-27
US20170240615A1 (en) 2017-08-24
US9499606B2 (en) 2016-11-22
EP1660094A4 (en) 2009-09-16
US20100137192A1 (en) 2010-06-03
US20200079836A1 (en) 2020-03-12
US8633305B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
PL2520654T3 (pl) Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
IL162828A0 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
IL173490A0 (en) 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
TWI346663B (en) P38 inhibitors and methods of use thereof
GB0612417D0 (en) Compositions and methods for topical treatment of skin infection
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
IS7620A (is) Qínólín afleiður og notkun þeirra sem tálma sveppagerla
AU2003303128A8 (en) Inhibitors and methods of use thereof
AU2003257937A8 (en) Methods and compositions for treatment of dermal conditions
EP1696910A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS
AU6008101A (en) Benzophenones as inhibitors of il-1beta and tnf-alpha
EP1531828A4 (en) METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
EP1613266A4 (en) METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
AU1101501A (en) Methods and compositions for treatment of keratoconus using protease inhibitors
EP1567183A4 (en) METHOD AND COMPOSITIONS FOR TREATING OTITIS MEDIA
PL1628965T3 (pl) Związki hydroksyamidynowe i hydroksyguanidynowe jako inhibitory urokinazy
AU2003301903A8 (en) Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
GB0324523D0 (en) Compositions and methods of treatment
AU2003222171A8 (en) Compositions and methods for portal specific gene delivery and treatment of infection
IL151436A0 (en) Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria
GB0411145D0 (en) Protease inhibitors and their therapeutic applications
EP1693437A4 (en) CIP CLEANER COMPOSITION AND METHOD FOR CLEANING THEREWITH